{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:07:23Z","timestamp":1789607243947,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Leo Pharma AB","award":["SAHL1011"],"award-info":[{"award-number":["SAHL1011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts patients\u2019 quality of life. While TNF-\u03b1 inhibitors are frequently used to treat moderate-to-severe cases, not all patients respond adequately. Brodalumab, a monoclonal antibody targeting the IL-17 receptor A, has emerged as an alternative for individuals unresponsive to prior therapies. This prospective study investigated the effects of brodalumab on serum cytokine levels\u2014specifically IL-6, IL-17A, IFN-\u03b1, IFN-\u03b3, and TNF-\u03b1\u2014and their correlation with disease severity as assessed by Psoriasis Area and Severity Index (PASI). Eighteen patients with moderate-to-severe psoriasis who were unresponsive to TNF-\u03b1 inhibitors received brodalumab for 12 weeks. Cytokine concentrations were measured at baseline and week 12 using an automated immunoassay (ELLA), and clinical outcomes were evaluated using PASI. The results showed a significant increase in IL-17A levels, while changes in IL-6, IFN-\u03b1, IFN-\u03b3, and TNF-\u03b1 did not reach statistical significance. No significant correlations were found between changes in cytokine levels and PASI improvement. However, the small number of available serum samples at week 12 (n = 11) limited the statistical power to detect treatment-related changes in cytokine levels. These findings suggest that while brodalumab influences specific immune markers, the clinical response may not be directly reflected by serum cytokine levels. This highlights the multifactorial nature of psoriasis pathogenesis and underscores the need for further studies to clarify the role of cytokine biomarkers in treatment response.<\/jats:p>","DOI":"10.3390\/ijms27010458","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T11:11:46Z","timestamp":1767352306000},"page":"458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Brodalumab on Serum Levels of IL-6, IL-17A, IFN-\u03b1, IFN-\u03b3, and TNF-\u03b1 in Patients with Psoriasis Who Failed Treatment with TNF-\u03b1 Inhibitors"],"prefix":"10.3390","volume":"27","author":[{"given":"Lucia","family":"Medjedovic","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admir","family":"Vi\u017elin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylva","family":"Andersch Bj\u00f6rkman","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"},{"name":"Department of Dermatology and Venereology, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maj","family":"Albertsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-5421","authenticated-orcid":false,"given":"Martin","family":"Gillstedt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"},{"name":"Department of Dermatology and Venereology, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amra","family":"Osmancevic","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"},{"name":"Department of Dermatology and Venereology, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Michalek, I., Loring, B., and John, S. (2025, December 25). WHO Global Report on Psoriasis, Available online: https:\/\/www.who.int\/publications\/i\/item\/global-report-on-psoriasis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis-Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/jid.2011.468","article-title":"IFN-\u03b1 enhances IL-22 receptor expression in keratinocytes: A possible role in the development of psoriasis","volume":"132","author":"Tohyama","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 Family of Cytokines in Health and Disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_9","unstructured":"Duvetorp, A., Osmancevic, A., Stymne, B., Enerb\u00e4ck, C., Lysell, J., Sandberg, S., Talme, T., S\u00e4rnhult, T., and Svensson, \u00c5. (2024). SSDV:s Behandlingsrekommendationer f\u00f6r Systemisk Behandling av Psoriasis (2024-12-15), Swedish Society for Dermatology and Venereology (SSDV)."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jdv.16966","article-title":"Psoriasis severity: Commonly used clinical thresholds may not adequately convey patient impact","volume":"35","author":"Golbari","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e15106","DOI":"10.1111\/dth.15106","article-title":"Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis","volume":"34","author":"Loft","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: A 6-year real-world cohort study","volume":"99","author":"Alves","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/tpj.2017.31","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ad.2025.03.030","article-title":"Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice","volume":"116","author":"Armesto","year":"2025","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/1346-8138.16917","article-title":"Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF-\u03b1 inhibitors","volume":"50","author":"Micu","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2015). Clinical Pharmacology and Biopharmaceutics Review: Brodalumab (Siliq), Application Number 761032, Original BLA."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jdermsci.2025.09.005","article-title":"Molecular profile of interleukin-17RA blockade by brodalumab in Japanese patients with psoriasis: Results from the ESPRIT study","volume":"120","author":"Krueger","year":"2025","journal-title":"J. Dermatol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjd.21060","article-title":"Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum","volume":"187","author":"Navrazhina","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: A review and update","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T11:12:16Z","timestamp":1767352336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010458"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010458","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}